For example, in a retrospective study performed on 95 patients with pre-treated pMMR CRC receiving an anti-PD1/PDL1 therapy, the overall response rate was of 19.5% in patients without liver metastases, and no response (0%) was observed among the 54 patients with liver metastases [18]. This evidence concerns the gene CD274 and colorectal carcinoma.